

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 October 2023 (05.10.2023)



(10) International Publication Number
WO 2023/192491 A2

(51) International Patent Classification:
A61K 31/522 (2006.01) *A61K 31/519* (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2023/016921

Published:

(22) International Filing Date:
30 March 2023 (30.03.2023)

— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/325,442 30 March 2022 (30.03.2022) US

(71) Applicant: **TRANSPONSON THERAPEUTICS, INC.**
[US/US]; 4660 La Jolla Village Drive, Suites 100 & 200,
San Diego, California 92122 (US).

(72) Inventors: **WEBER, Eckard**; 8218 Hollywood Boule-
vard, Los Angeles, California 90069 (US). **CORDING-
LEY, Michael, G.**; 320 Rue Robert Ouest, Rosemère,
Québec J7A 1C9 (CA). **BURNIE, Andrew, James**; 2525
Marie-Curie, Montreal, Québec H4S 2E1 (CA). **BROWN,
William**; 2525 Marie-Curie, Montreal, Québec H4S 2E1
(CA). **DARAPANENI, Chandra Mohan**; 2525 Marie-
Curie, Montreal, Québec H4S 2E1 (CA). **PALADINO,
Marco**; 2525 Marie-Curie, Montreal, Québec H4S 2E1
(CA). **DOSHI, Malay**; 201 Metric Circle, Ottawa, On-
tario K2V 0L3 (CA). **PATEL, Jigneshkumar Jashbhai**; 7
Yardley Crescent, Brampton, Ontario L6X 5L6 (CA).

(74) Agent: **GROSS, Michael, F., III** et al.; Sterne, Kessler,
Goldstein & Fox P.L.L.C., 1100 New York Avenue, NW,
Washington, District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: NUCLEOSIDE LINE-1 INHIBITORS

(57) Abstract: The present disclosure provides LINE-1 inhibitors and methods of treating or preventing a disease, disorder, or condition in a subject in need thereof, the methods comprising administering to the subject a therapeutically effective amount of a LINE-1 inhibitor.

WO 2023/192491 A2